Gemcitabine

3 articles published between March 2, 2026 and July 29, 2026.

WHAT THE STUDY ACTUALLY SAYS

Drug pair beat cisplatin chemo before bladder surgery in a head-to-head trial

In KEYNOTE-B15/EV-304, perioperative enfortumab vedotin plus pembrolizumab lifted two-year event-free survival to 79.4% from 66.2% against standard cisplatin-based chemotherapy in patients fit for it.

3 min read

WHAT THE STUDY ACTUALLY SAYS

Drug therapy before surgery delayed relapse in high-risk bile-duct cancer

In a Chinese phase 2–3 trial, neoadjuvant chemotherapy, lenvatinib and a PD-1 antibody before liver surgery lifted median event-free survival to 18.0 months from 8.7. The survival signal was not yet conclusive.

3 min read

WHAT THE STUDY ACTUALLY SAYS

Immunotherapy added to chemo extended remission in advanced nasopharyngeal cancer

A three-year update of RATIONALE-309 found tislelizumab plus chemotherapy lengthened median progression-free survival to 9.6 months from 7.4. The overall-survival gain was not statistically significant on its own.

3 min read

This page indexes this newspaper’s reporting on Gemcitabine. It is not a medical reference entry, and nothing here is medical advice. See our editorial standards.

Gemcitabine

Drug pair beat cisplatin chemo before bladder surgery in a head-to-head trial

Drug therapy before surgery delayed relapse in high-risk bile-duct cancer

Immunotherapy added to chemo extended remission in advanced nasopharyngeal cancer

Reported alongside